The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effects of Pyridoxamine in Combined Phase 2 Studies of Patients with Type 1 and Type 2 Diabetes and Overt Nephropathy
Abstract
Background/Aims: Treatments of diabetic nephropathy (DN) delay the onset of end-stage renal disease. We report the results of safety/tolerability studies in patients with overt nephropathy and type 1/type 2 diabetes treated with pyridoxamine, a broad inhibitor of advanced glycation. Methods: The two 24-week studies were multicenter Phase 2 trials in patients under standard-of-care. In PYR-206, patients were randomized 1:1 and had baseline serum creatinine (bSCr) ≤2.0 mg/dl. In PYR-205/207, randomization was 2:1 and bSCr was ≤2.0 for PYR-205 and ≧2.0 but ≤3.5 mg/dl for PYR-207. Treated patients (122 active, 90 placebo) received 50 mg pyridoxamine twice daily in PYR-206; PYR-205/207 patients were escalated to 250 mg twice daily. Results: Adverse events were balanced between the groups (p = NS). Slight imbalances, mainly in the PYR-205/207 groups, were noted in deaths (from diverse causes, p = NS) and serious adverse events (p = 0.05) that were attributed to pre-existing conditions. In a merged data set, pyridoxamine significantly reduced the change from baseline in serum creatinine (p < 0.03). In patients similar to the RENAAL/IDNT studies (bSCr ≧1.3 mg/dl, type 2 diabetes), a treatment effect was observed on the rise in serum creatinine (p = 0.007). No differences in urinary albumin excretion were seen. Urinary TGF-β1 also tended to decrease with pyridoxamine (p = 0.049) as did the CML and CEL AGEs. Conclusion: These data provide a foundation for further evaluation of this AGE inhibitor in DN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
The Pathobiology of Diabetic Complications
Brownlee, M. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1615 · Cited by 5,339
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
Advanced protein glycosylation in diabetes and aging
Brownlee, M. D. (1995) · Annual Review of Medicine · doi:10.1146/annurev.med.46.1.223 · Cited by 1,312
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Ziyadeh, F. N., Hoffman, B. B., Han, D. C., Iglesias-de la Cruz, M. C., Hong, S. W., Isono, M., Chen, S., McGowan, T. A., & Sharma, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120055097 · Cited by 907
Maillard reaction products in tissue proteins: New products and new perspectives
Thorpe, S. R., & Baynes, J. W. (2003) · Amino Acids · doi:10.1007/s00726-003-0017-9 · Cited by 543
Monnier, V. M., Bautista, O., Kenny, D., Sell, D. R., Fogarty, J., Dahms, W., Cleary, P. A., Lachin, J., & Genuth, S. (1999) · Diabetes · doi:10.2337/diabetes.48.4.870 · Cited by 469
Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats.
Vlassara, H., Striker, L. J., Teichberg, S., Fuh, H., Li, Y. M., & Steffes, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11704 · Cited by 462
Bolton, W. K., Cattran, D. C., Williams, M. E., Adler, S. G., Appel, G. B., Cartwright, K., Foiles, P. G., Freedman, B. I., Raskin, P., Ratner, R. E., et al. (2004) · American Journal of Nephrology · doi:10.1159/000075627 · Cited by 461
Self-citationDicarbonyl Intermediates in the Maillard Reaction
THORNALLEY, P. J. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1333.014 · Cited by 459
Genuth, S., Sun, W., Cleary, P., Sell, D. R., Dahms, W., Malone, J., Sivitz, W., Monnier, V. M., & for the DCCT Skin Collagen Ancillary Study Group (2005) · Diabetes · doi:10.2337/diabetes.54.11.3103 · Cited by 427
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat
Degenhardt, T. P., Alderson, N. L., Arrington, D. D., Beattie, R. J., Basgen, J. M., Steffes, M. W., Thorpe, S. R., & Baynes, J. W. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00207.x · Cited by 378
Self-citationRole of Advanced Glycation End Products in Diabetic Nephropathy
Forbes, J. M., Cooper, M. E., Oldfield, M. D., & Thomas, M. C. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000077413.41276.17 · Cited by 351 · cited 1×
“the mechanisms of damage continue to be investigated. A growing body of evidence has accumulated, implicating the nonenzymatic formation of advanced glycation end products (AGEs) as a major factor in the development of long-term diabetic complications [ , ,”
BackgroundAchieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HCl
Moe, S. M., Chertow, G. M., Coburn, J. W., Quarles, L. D., Goodman, W. G., Block, G. A., DrEke, T. B., Cunningham, J., Sherrard, D. J., Mccary, L. C., et al. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.67139.x · Cited by 327
Advanced glycation end products: A nephrologist's perspective
Raj, D. S. C., Choudhury, D., Welbourne, T. C., & Levi, M. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70189-2 · Cited by 290
Amadorins: Novel Post-Amadori Inhibitors of Advanced Glycation Reactions
Khalifah, R. G., Baynes, J. W., & Hudson, B. G. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0371 · Cited by 268
Self-citationNovel α2-adrenoreceptors primarily responsible for inducing human platelet aggregation
GRANT, J. A., & SCRUTTON, M. C. (1979) · Nature · doi:10.1038/277659a0 · Cited by 207
Intervention against the Maillard reaction in vivo
Monnier, V. M. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.08.014 · Cited by 196
Metz, T. O., Alderson, N. L., Thorpe, S. R., & Baynes, J. W. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.08.021 · Cited by 191
Susceptibility to Diabetic Nephropathy Is Related to Dicarbonyl and Oxidative Stress
Beisswenger, P. J., Drummond, K. S., Nelson, R. G., Howell, S. K., Szwergold, B. S., & Mauer, M. (2005) · Diabetes · doi:10.2337/diabetes.54.11.3274 · Cited by 189
Voziyan, P. A., & Hudson, B. G. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5082-7 · Cited by 187
Advanced glycation end products and the progressive course of renal disease
Heidland, A., Sebekova, K., & Schinzel, R. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.27414 · Cited by 168
Caramori, M. L., & Mauer, M. S. (2003) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200305000-00008 · Cited by 155
Kelly, D. J., Gilbert, R. E., Cox, A. J., Soulis, T., Jerums, G., & Cooper, M. E. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v12102098 · Cited by 128
Degenhardt, T. P., Grass, L., Reddy, S., Thorpe, S. R., Diamandis, E. P., & Baynes, J. (1997) · Kidney International · doi:10.1038/ki.1997.429 · Cited by 107
Self-citationAlderson, N. L., Chachich, M. E., Frizzell, N., Canning, P., Metz, T., Januszewski, A. S., Youssef, N., Stitt, A. W., Baynes, J., & Thorpe, S. R. (2004) · Diabetologia · doi:10.1007/s00125-004-1474-8 · Cited by 96
Pimagedine: a novel therapy for diabetic nephropathy
Bolton, W. K., & Abdel‐Rahman, E. M. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.4.565 · Cited by 82
Self-citationZheng, F., Zeng, Y.-J., Plati, A. R., Elliot, S. J., Berho, M. E., Potier, M., Striker, L. J., & Striker, G. E. (2006) · Kidney International · doi:10.1038/sj.ki.5001578 · Cited by 79
Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding
Youssef, S., Nguyen, D. T., Soulis, T., Panagiotopoulos, S., Jerums, G., & Cooper, M. E. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.055003907.x · Cited by 74
Role of lipids in chemical modification of proteins and development of complications in diabetes
Januszewski, A. S., Alderson, N. L., Metz, T., Thorpe, S. R., & Baynes, J. (2003) · Biochemical Society Transactions · doi:10.1042/bst0311413 · Cited by 73
Khalifah, R. G., Chen, Y., & Wassenberg, J. J. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1333.092 · Cited by 35
Self-citationNew therapies for advanced glycation end product nephrotoxicity: Current challenges
Williams, M. E. (2003) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2003.50083 · Cited by 30
Self-citationNakamura, S., Tachikawa, T., Tobita, K., Aoyama, I., Takayama, F., Enomoto, A., & Niwa, T. (2003) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2003.50088 · Cited by 18
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
Natural products: An evolving role in future drug discovery
Mishra, B. B., & Tiwari, V. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.057 · Cited by 860
Metadata
- Authors
- Williams, M. E., Bolton, W. K., Khalifah, R. G., Degenhardt, T. P., Schotzinger, R. J., & McGill, J. B.
- Venue
- American Journal of Nephrology
- Publisher
- S. Karger AG
- Published
- 2007
- Volume
- 27
- Issue
- 6
- Pages
- 605-614
- ISSN
- 0250-8095 (ISSN-L)
- 1421-9670
- OpenAlex
- W1990313130
- Cited by
- 253
- References
- 38
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.